Effect of Antibiotic Susceptibility and CYP3A4/5 and CYP2C19 Genotype on the Outcome of Vonoprazan-Containing Helicobacter pylori Eradication Therapy

Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan

(2019) Mitsushige Sugimoto et al.   Frontiers in Pharmacology

Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori

(2018) Min Li et al.   HELICOBACTER

Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori

(2018) Soichiro Sue et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?

(2017) Shou Quan Dong et al.   HELICOBACTER

Efficacy of the Kyoto Classification of Gastritis in Identifying Patients at High Risk for Gastric Cancer

(2017) Mitsushige Sugimoto et al.   INTERNAL MEDICINE

Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype

(2016) T. Kagami et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Successful eradication of Helicobacter pylori infection with vonoprazan-based triple therapy after failure of PPI-based triple therapy

(2016) Kousaku Kawashima et al.   DIGESTIVE AND LIVER DISEASE

Efficacy of vonoprazan-based second-line Helicobacter pylori eradication therapy in patients for whom vonoprazan-based first-line treatment failed

(2016) Yasumi Katayama et al.   GUT

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy forHelicobacter pylorieradication: a phase III, randomised, double-blind study

(2016) Kazunari Murakami et al.   GUT

Vonoprazanversusconventional proton pump inhibitor-based triple therapy as first-line treatment againstHelicobacter pylori: A multicenter retrospective study in clinical practice

(2016) Satoki Shichijo et al.   Journal of Digestive Diseases

Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori

(2016) Satoshi Shinozaki et al.   KAOHSIUNG JOURNAL OF MEDICAL SCIENCES

Analysis of the cost-effectiveness of using vonoprazan–amoxicillin–clarithromycin triple therapy for first-line Helicobacter pylori eradication

(2016) Yusaku Kajihara et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker

(2016) Hitomi Yamasaki et al.   XENOBIOTICA

Safety and efficacy of Vonoprazan-based triple therapy against Helicobacter pylori infection: A single-center experience with 1118 patients

(2016) Daisuke Fukuda et al.   Therapeutic Advances in Gastroenterology

HighHelicobacter pyloricure rate with sitafloxacin-based triple therapy

(2015) M. Sugimoto et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy of 10-day Sitafloxacin-Containing Third-Line Rescue Therapies forHelicobacter pyloriStrains Containing thegyrAMutation

(2015) Hideki Mori et al.   HELICOBACTER

Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole

(2014) S. Sahara et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The Role of Pharmacogenetics in the Disposition of and Response to Tacrolimus in Solid Organ Transplantation

(2013) Dennis A. Hesselink et al.   CLINICAL PHARMACOKINETICS

Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan

(2013) Kazunari Murakami et al.   JOURNAL OF GASTROENTEROLOGY

Sitafloxacin-based third-line rescue regimens forHelicobacter pyloriinfection in Japan

(2013) Takahisa Furuta et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Association of Helicobacter pylori dupA With the Failure of Primary Eradication

(2012) Seiji Shiota et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part I

(2010) Christine E. Staatz et al.   CLINICAL PHARMACOKINETICS

1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases

(2010) Y. Hori et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

(2010) D Wang et al.   PHARMACOGENOMICS JOURNAL

Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy

(2009) Mitsushige Sugimoto et al.   ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS